MINDLIGHT Trademark

Trademark Overview

On Wednesday, June 5, 2024, a trademark application was filed for MINDLIGHT with the United States Patent and Trademark Office. The USPTO has given the MINDLIGHT trademark a serial number of 98585696. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, June 5, 2024. This trademark is owned by Circular Genomics, Inc.. The MINDLIGHT trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Medical laboratory analysis services relating to the treatment of persons, namely, detecting circular RNA biomarkers for medical purposes; Medical laboratory analysis services relating to the treatment of persons, namely, detecting circular RNA biomarkers for the diagnosis of psychiatric and neurological disorders; Medical laboratory analysis services relating to the treatment of persons, namely, namely detecting circular RNA biomarkers for the diagnostic assessment of a major depressive disorder (MDD); Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples to determine if the patient will respond to selective serotonin reuptake inhibitor (SSRI) treatment; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for the diagnosis of psychiatric and neurological disorders; Medical laboratory analysis services relating to the treatm...
mindlight

General Information

Serial Number98585696
Word MarkMINDLIGHT
Filing DateWednesday, June 5, 2024
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateWednesday, June 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesMedical laboratory analysis services relating to the treatment of persons, namely, detecting circular RNA biomarkers for medical purposes; Medical laboratory analysis services relating to the treatment of persons, namely, detecting circular RNA biomarkers for the diagnosis of psychiatric and neurological disorders; Medical laboratory analysis services relating to the treatment of persons, namely, namely detecting circular RNA biomarkers for the diagnostic assessment of a major depressive disorder (MDD); Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples to determine if the patient will respond to selective serotonin reuptake inhibitor (SSRI) treatment; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for the diagnosis of psychiatric and neurological disorders; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for the diagnosis of a major depression disorder; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers for medical purposes; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for the diagnosis of psychiatric and neurological disorders; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for major depressive disorders (MDD); Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples to determine if the patient will respond to selective serotonin reuptake inhibitor (SSRI) treatment; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for predicting patient response to selective serotonin reuptake inhibitor (SSRI) and disease prognosis based on SSRI treatment; and Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for predicting patient response to SSRI for treatment of major depressive disorder (MDD) and predicting disease prognosis following treatment

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, June 5, 2024
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCircular Genomics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAlbuquerque, NM 87110

Trademark Events

Event DateEvent Description
Wednesday, June 5, 2024NEW APPLICATION ENTERED

Related Keywords

mindlight medical treatment relating namely laboratory analysis services biomarkers circular detecting